Veracyte Presents New Data Findings Are From The Prospective, Multicenter VANDAAM Trial, Show That Its Decipher Prostate Test Predicts Aggressive Prostate Cancer In African American Men At ASTRO 2024
Veracyte Presents New Data Findings Are From The Prospective, Multicenter VANDAAM Trial, Show That Its Decipher Prostate Test Predicts Aggressive Prostate Cancer In African American Men At ASTRO 2024
Findings are from the prospective, multicenter VANDAAM trial
這些發現來自前瞻性、多中心的VANDAAm試驗。
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced that new data from the multicenter, prospective VANDAAM trial show that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among African American men with early-stage disease. The findings confirm that the market-leading genomic test offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions for African American men, a population that is disproportionately impacted by the disease. The new data were shared today in an oral presentation at ASTRO 2024, the annual meeting of the American Society for Radiation Oncology, in Washington, D.C.
領先的癌症診斷公司Veracyte, Inc.（納斯達克: VCYT）宣佈，來自多中心、前瞻性VANDAAm試驗的新數據顯示，Decipher前列腺基因分類器可以準確預測早期疾病中非洲裔美國男性患有侵襲性前列腺癌的風險。這些發現證實了這一市場領先的基因測試爲臨床醫生在指導非洲裔美國男性的前列腺癌治療決策方面比單純依靠臨床因素有所改進，而這一人群所受疾病影響顯著。新數據今天在美國放射腫瘤學會（ASTRO）2024年年會上以口頭報告形式分享，在華盛頓特區舉行。
African American men are more than 70% as likely to be diagnosed with prostate cancer and more than twice as likely to die of the disease, compared to white men, according to the American Cancer Society.1 Despite this, few prospective studies have specifically sought to examine the disease at a genomic level in this population.
根據美國癌症協會的數據，與白人男性相比，非洲裔美國男性被診斷患有前列腺癌的概率高出70%以上，死於該疾病的概率是白人男性的兩倍以上。儘管如此，仍然很少有前瞻性研究專門探討了在該人群中對該疾病進行基因組水平的研究。
